Taro announces merger agreement with Sun Pharma
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Subscribe To Our Newsletter & Stay Updated